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ABSTRACT
Treatment options for patients with thyroid cancer that is no longer sensitive to iodine therapy are limited. Those
treatments which currently exist are associated with significant toxicity. The SELIMETRY trial (EudraCT No 2015-002269-47)
aims to investigate the role of the MEK inhibitor Selumetinib in resensitizing advanced iodine refractory differentiated
thyroid cancer to radioiodine therapy. Patients deemed to have sufficient iodine uptake in previously iodine refractory
lesions after 4 weeks of Selumetinib therapy will be given an empirical activity of 5.5GBq I-131, and response to therapy
will be assessed. The trial presents an opportunity to investigate the dosimetric aspects of radioiodine therapy for
advanced thyroid cancer. Patients will undergo serial I-123 single-photon emission CT (SPECT)/CT scans following
Selumetinib therapy to determine whether there has been a change in the degree of iodine uptake to justify further I-131
therapy, and to allow dosimetric calculations to predict absorbed dose to target lesions following therapy. Patients
receiving I-131 therapy will undergo a further series of post-therapy SPECT/CT scans to allow dosimetric calculations. We
describe the challenges in setting up a multicentre trial in a relatively underinvestigated field, describing the work that has
been carried out to calibrate and validate measurements to ensure that standardized image data are collected at each
site. We hope that this trial will lead to individualization and optimization of therapy for patients with advanced thyroid
cancer and that the ground work carried out in setting up a network of centres capable of standardized molecular
radiotherapy dosimetry will lead to further clinical trials in this field.
THE SELIMETRY TRIAL
Differentiated thyroid cancer is the most common endo-
crine malignancy, with 3200 patients diagnosed in the UK
in 2012.1 Most patients, presenting with early disease, are
cured by surgical resection of part of or the whole thyroid.
In selected cases, this is followed by radioiodine ablation
therapy. Around 5–10% of patients will develop more
advanced disease not amenable to complete surgical
resection.
I-131 is an important treatment for advanced differentiated
thyroid cancer, proving curative in a proportion of patients
and controlling the disease for several years in many more.
Unfortunately, a significant number of cancers will not
respond to I-131 in the first instance or become resistant
following a number of I-131 therapies. This is described as
iodine refractory differentiated thyroid cancer (RR-DTC).
Currently, treatment options for this group of patients are
limited.
The SELIMETRY trial (EudraCT No 2015-002269-47) is
a multicentre Phase 2 trial investigating the potential for
Selumetinib to resensitize RR-DTC cells to radioiodine
therapy. Selumetinib is an oral agent that selectively
inhibits MEK, a target in the MAPK signalling pathway.
Aberrations in this pathway are known to be associated
with loss of uptake of iodine by thyroid cancer cells. Lab-
oratory work and a pilot study in humans have shown
promising results.2 In the pilot study, 20 patients with
advanced RR-DTC were treated with Selumetinib 75mg
twice a day for 28 days. Patients underwent an I-124
positron emission tomography (PET) scan before and after
treatment. Those patients predicted to achieve a lesional dose of
20Gy or greater on the basis of the post-treatment I-124 PET
scan went on to receive further I-131 therapy. 8 (40%) of the
20 patients went on to receive I-131 therapy, all with evidence of
either radiological response or disease stabilization.
The SELIMETRY trial aims to replicate these findings in a mul-
ticentre setting, with a larger cohort of 60 patients, to demon-
strate the ability of Selumetinib and further I-131 to prolong
progression-free survival, and to further investigate and develop
the dosimetric aspects of the treatment.
I-131 DOSIMETRY
I-131 has been used as an effective treatment for thyroid cancer
since the 1940s. It is used both in the adjuvant setting, to reduce
the risk of recurrence after surgery, and as a treatment for
metastatic disease. Current UK guidelines recommend the use of
empirical activities of I-131, since “the role of dosimetry and its
impact on clinical outcomes compared to empirical use of I-131
therapy is unclear”.3
However, the use of an empirical activity for therapy is known
to lead to a very wide variation in absorbed dose delivered to
the target. One study investigating absorbed dose to thyroid
remnant showed that for a fixed activity administration,
absorbed dose to the thyroid remnant varied from 1.2 Gy to
540 Gy.4 Since response to therapy is very likely to be de-
termined by absorbed dose delivered to the target, it is critical
that we have a clearer understanding of the dose delivered
both to tumour and to organs at risk. This has led to calls for
further development of dosimetry techniques for molecular
radiotherapy.5,6
In the SELIMETRY trial, patients found to have increased iodine
uptake on post-Selumetinib imaging will undergo a series of 3–4
single-photon emission CT (SPECT)/CT scans (Table 1), to
allow calculation of predicted absorbed dose to each lesion
identified when I-131 therapy is administered.
In the absence of any evidence to support a dose threshold
required for effective therapy, all patients judged to have in-
creased iodine uptake on post-Selumetinib imaging at central
review will go on to receive an empirical activity of 5.5 GBq
I-131 therapy. Patients without increased uptake will continue to
be treated as per local practice. Three or four further SPECT/CT
scans (Table 1) will be taken post-therapy to determine that
actual absorbed dose to identified lesions.
Patients will then be followed up clinically and with regular
imaging to determine the radiological and biochemical response
rate, as determined by changes in the thyroid-specific tumour
marker, thyroglobulin. This will allow the exploration of the
relationship between response rate and absorbed dose, to assess
whether there may be a threshold absorbed dose level necessary
for response.
In addition, whole-body count readings will be made through-
out the patient hospital stay to calculate their whole-body dose.
This dose may correlate with myelotoxicity and therefore could
be used to calculate the maximum tolerated activity that could
be administered to the patient.
CHALLENGES
Historical barriers to dosimetry
Molecular radiotherapy plays an increasingly important role in
the treatment of a number of malignancies. Although outcome
for any given patient is dependent on the absorbed doses de-
livered rather than on activity administered, dosimetry has not
been implemented routinely as is mandatory for external beam
radiotherapy. A number of reasons have led to this anomaly,
stemming from a lack of reimbursement and a lack of legal
requirements for imaging or dosimetry calculations.
Table 1. Patient scanning schedule
Baseline I-123 scan (under rhTSH stimulation)
246 4 h (post-I-123) WB and SPECT/CT scan
4 weeks on Selumetinib
Post-Selumetinib 43 I-123 scans (under rhTSH)
56 1 h (post-I-123) WB and SPECT/CT scan
246 4 h (post-I-123) to be compared with the baseline scan
WB and SPECT/CT scan (match the baseline time between injection and
scanning)
486 4 h (post-I-123) SPECT/CT
726 4 h (post-I-123) SPECT/CT
Iodine-131 therapy administration (5.5 GBq) (under rhTSH stimulation) and dosimetry scans
246 4 h (post-I-131) dead-time permitting WB and SPECT/CT scan
486 4 h (post-I-131) SPECT/CT
726 4 h (post-I-131) SPECT/CT
1446 24 h (post-I-131) SPECT/CT
rhTSH, recombinant human thyroid stimulating hormone; SPECT, single-photon emission CT; WB, Whole Body.
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There are a number of significant differences in the radia-
tion delivery from molecular radiotherapy when compared
with external beam radiotherapy. Radionuclides deliver a
continuous, variable low-dose rate radiation to the tumour,
and this dose rate is patient dependent. It is affected by
multiple factors including the perfusion of the tumour, the
affinity of the vector, the cellular washout rate and the half-
life of the radionuclide. It increases during the uptake phase
and decreases subsequently, necessitating determination of a
time–activity curve.
To date, there have been no multicentre trials to investigate
dose–effect correlations in radioiodine treatment of thyroid
cancer, although there is increasing evidence of such correla-
tions.7 Current guidelines recommend the administration of
empirical activity of I-131 in the absence of any evidence base
for dosimetry-based prescribing.
Scanning facilities
It had initially been hoped to use I-124 PET imaging pre- and
post-Selumetinib therapy, as in the pilot study reported above,
as this allows higher resolution imaging and potentially more
accurate predictive dosimetry. However, there is currently no
commercial supplier of I-124, and many UK centres have
limited access to PET scanning facilities using tracers other
than fludeoxyglucose. A pragmatic decision was therefore taken
to use I-123 SPECT/CT, which is widely available in UK centres
and should give adequate information to guide treatment
decisions.8
Funding
A significant investment of time has been required to calibrate
and validate SPECT/CT measurements at each site to ensure
consistent dosimetry and permit multicentre data interpretation.
The requirement for serial SPECT/CT scans is demanding of
scanner time and expensive, but necessary to allow adequate
dosimetry calculations. The work has been generously supported
by a CRUK grant, Astrazeneca, who have provided the Selu-
metinib, and a further per-patient grant to support the study,
and Genzyme, who have supplied recombinant TSH for use
before scans and therapy.
It is hoped that once a network of centres capable of stan-
dardized dosimetry is established, the costs of supporting future
trials will be reduced.
Standardization
It is clearly critical that image data collected at each study site is
optimized and standardized to allow accurate dosimetry calcu-
lations. Early in the trial development, a meeting of medical
physicists from each of the participating centres, along with
a representative from National Physical Laboratory and the
National Cancer Research Institute Radiotherapy Trials Quality
Assurance group, was convened to discuss scanning protocols
and ensure that protocol requirements could be met at every
site. This meeting proved invaluable, allowing sharing of best
practice and development of a workable protocol.
Subsequently, each site has been visited prior to study
opening to calibrate and validate SPECT/CT measurements.
Prior to the visit, centres are required to perform routine
quality control measurements and to ensure that their
SPECT/CT system is set up with the appropriate parame-
ters (Table 2).
During the visit, I-131 dead-time is characterized based on
count rate measurements for increased activity (up to 2.8 GBq)
in a cylindrical (20 cm diameter, 20 cm long) phantom. I-131
and I-123 calibration factors to correct partial volume and
resolution effects are also measured. These are determined
from SPECT/CT images of known activity concentrations of
I-131 or I-123 in cylindrical inserts, with volumes from 0.5ml
to 196ml, positioned in a non-active water-filled anthropo-
morphic phantom.
To ensure that consistent decisions are made about which
patients should go on to receive I-131 following Selumetinib, it
has been decided that post-Selumetinib SPECT/CT scans will
be centrally reviewed in real time. Whilst logistically chal-
lenging, this is felt to be important to ensure the credibility of
the final results. With the use of electronic transfer of imaging
data, we believe that this will be feasible within the necessary
timeframes.
Table 2. Scanning parameters
Parameter I-123 I-131
Collimator MEGP HEGP
Peak energy window (20%) 159 keV (138.9–180.3 keV) 364 keV(327.6–400.5 keV)
Low scatter energy window (6%) 67.4–138.9 keV 308.5–327.6 keV
High scatter energy window (6%) 180.3–348.9 keV 400.6–425.4 keV
Matrix 128 3 128
SPECT movement Body contour (or radius as close to the phantom as possible)
Projections 72 (5°/projection)
Time per projection 60 s
CT Standard low-dose protocol
HEGP, high-energy general purpose; MEGP, medium-energy general purpose; SPECT, single-photon emission CT.
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SUMMARY
The SELIMETRY trial presents a unique opportunity to develop
the infrastructure and expertise necessary in UK nuclear medi-
cine centres to allow I-131 dosimetry calculations to be per-
formed so that absorbed dose to target lesions can be reported in
a consistent and reproducible manner.
It is hoped that this study will lead towards defining a dose
threshold for successful treatment of advanced thyroid cancer
and to individualizing administered activity for future patients
to ensure that this dose threshold is reached whilst minimizing
toxicity.
It is also hoped that having developed a network of centres
capable of standardized dosimetry, further clinical trial protocols
will be developed to establish an evidence base for dosimetry-
guided molecular radiotherapy.
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The SELIMETRY trial is supported by a Cancer Research UK
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